AKT1 and colorectal carcinoma: High-throughput RNA sequencing revealed that tRF-T36 targets NUCKS1 to inhibit PI3K/Akt pathway, which was further validated through a rescue experiment using 740Y-P, a PI3K/Akt agonist, indicating the potential of tRF-T36 as a siRNA drug candidate for CRC therapy.